Literature DB >> 8710748

Analysis of intestinal perfusion data for highly permeable drugs using a numerical aqueous resistance--nonlinear regression method.

P J Sinko1, G D Leesman, A P Waclawski, H Yu, J H Kou.   

Abstract

PURPOSE: To develop, validate and apply a method for analyzing the intestinal perfusion data of highly permeable compounds using the Numerical Aqueous Resistance (NAR) theory and nonlinear regression (NAR-NLR) and to compare the results with the well-established Modified Boundary Layer (MBL) Analysis.
METHODS: The NAR-NLR method was validated and the results were compared to the MBL analysis results using previously reported cephradine jejunal perfusion data. Using the Single Pass Intestinal Perfusion (SPIP) method, the concentration dependence of intestinal permeability was investigated for formycin B, proline, and thymidine, three compounds reported to be absorbed by carrier-mediated transport processes. The MBL and NAR-NLR analyses were then applied to the three sets of SPIP data.
RESULTS: The results demonstrate that the intrinsic MBL transport parameters were highly variable and, in one case, the analyses failed to give a statistically significant Michaelis constant. The MBL mean dimensionless wall permeabilities (P*w) were greater than the NAR-NLR P*w and were also highly variable. In all cases, the NAR-NLR variability was significantly lower than the MBL variability. The extreme variability in the MBL-calculated P*w is due to the sensitivity of P*w when the fraction of unabsorbed drug (Cm/Co) is low or, alternatively, when P*w approached the aqueous permeability, P*aq.
CONCLUSIONS: The NAR-NLR method facilitates the analysis of intestinal perfusion data for highly permeable compounds such as those absorbed by carrier-mediated processes at concentrations below their Km. The method also allows for the use of a wider range of flow conditions than the MBL analysis resulting in more reliable and less variable estimates of intestinal transport parameters as well as intestinal wall permeabilities.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8710748     DOI: 10.1023/a:1016098121784

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  6 in total

1.  Calculation of the aqueous diffusion layer resistance for absorption in a tube: application to intestinal membrane permeability determination.

Authors:  J H Kou; D Fleisher; G L Amidon
Journal:  Pharm Res       Date:  1991-03       Impact factor: 4.200

2.  Determination of intrinsic membrane transport parameters from perfused intestine experiments: a boundary layer approach to estimating the aqueous and unbiased membrane permeabilities.

Authors:  D A Johnson; G L Amidon
Journal:  J Theor Biol       Date:  1988-03-07       Impact factor: 2.691

3.  Theoretical model studies of intestinal drug absorption. IV. Bile acid transport at premicellar concentrations across diffusion layer-membrane barrier.

Authors:  N F Ho; W I Higuchi
Journal:  J Pharm Sci       Date:  1974-05       Impact factor: 3.534

4.  Characterization of the oral absorption of beta-lactam antibiotics. I. Cephalosporins: determination of intrinsic membrane absorption parameters in the rat intestine in situ.

Authors:  P J Sinko; G L Amidon
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

5.  Oral absorption of anti-AIDS nucleoside analogues. 1. Intestinal transport of didanosine in rat and rabbit preparations.

Authors:  P J Sinko; P Hu; A P Waclawski; N R Patel
Journal:  J Pharm Sci       Date:  1995-08       Impact factor: 3.534

6.  Membrane permeability parameters for some amino acids and beta-lactam antibiotics: application of the boundary layer approach.

Authors:  M Hu; P J Sinko; A L deMeere; D A Johnson; G L Amidon
Journal:  J Theor Biol       Date:  1988-03-07       Impact factor: 2.691

  6 in total
  1 in total

Review 1.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.